Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases.
Int J Mol Sci
; 24(7)2023 Mar 26.
Article
de En
| MEDLINE
| ID: mdl-37047224
There is a large unmet medical need to develop disease-modifying treatment options for individuals with age-related degenerative diseases of the central nervous system. The sigma-2 receptor (S2R), encoded by TMEM97, is expressed in brain and retinal cells, and regulates cell functions via its co-receptor progesterone receptor membrane component 1 (PGRMC1), and through other protein-protein interactions. Studies describing functions of S2R involve the manipulation of expression or pharmacological modulation using exogenous small-molecule ligands. These studies demonstrate that S2R modulates key pathways involved in age-related diseases including autophagy, trafficking, oxidative stress, and amyloid-ß and α-synuclein toxicity. Furthermore, S2R modulation can ameliorate functional deficits in cell-based and animal models of disease. This review summarizes the current evidence-based understanding of S2R biology and function, and its potential as a therapeutic target for age-related degenerative diseases of the central nervous system, including Alzheimer's disease, α-synucleinopathies, and dry age-related macular degeneration.
Mots clés
Alzheimer's disease (AD); Huntington's disease; MAC30; NiemannPick disease type C (NPC); PGRMC1; Parkinson's disease (PD); S2R; TMEM97; degenerative disease; dementia with Lewy bodies (DLB); dry age-related macular degeneration (dry AMD); prion protein, PrPC; schizophrenia; α-synuclein; σ2R
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Récepteur sigma
/
Maladie à corps de Lewy
/
Maladie d'Alzheimer
Limites:
Animals
Langue:
En
Journal:
Int J Mol Sci
Année:
2023
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique
Pays de publication:
Suisse